AstraZeneca’s breast cancer drug, Enhertu, co-developed with Daiichi Sankyo, has been officially added to China’s national health insurance program. This inclusion, effective January 2025, is part of the Chinese government’s efforts to make innovative treatments accessible to its population of 1.4 billion.

Enhertu, known for its targeted approach to delivering chemotherapy directly to HER-2 positive tumors, has been a game-changer for breast cancer patients worldwide. Its availability through the insurance scheme will enable thousands of Chinese women to receive this life-saving medication at a significantly reduced cost.

However, being part of the national insurance program often means substantial price reductions. For pharmaceutical companies like AstraZeneca, this poses a challenge of balancing affordability with profitability. Despite this, AstraZeneca remains committed to China’s growing market, which already contributes 13% of the company’s global revenue.

This development also highlights the broader strides China is making in healthcare accessibility. By focusing on affordability and innovation, the government aims to close gaps in treatment availability, especially for critical illnesses. AstraZeneca’s investment in China also reflects a global trend where pharmaceutical companies are increasingly prioritizing emerging markets as part of their growth strategies.

Read More News : Click Here